Chinese Gallnuts Pharma Grade API is prepared from the desiccated gall excrescence produced by Schlechtendalia chinensis on Rhus chinensis petioles. The material is standardised as a hydrolysable tannin fraction for tablet, capsule, granule, injection, oral, and injectable dosage forms. Supplier model codes generally encode the minimum gallotannin content determined by the hide-powder assay adapted from Ph. Eur. 2.8.14: CGT-90, CGT-95, and CGT-98 correspond to no less than 90.0%, 95.0%, and 98.0% gallotannins on the dried substance. The material is an amorphous, pale-cream to light-tan powder. Solid-dose grades are milled to a laser-diffraction D90 below 150 µm for direct blending, while injectable grades are further processed for low endotoxin and low bioburden. The product is a mixture of polygalloylglucose esters with molecular weights ranging from approximately 940 g/mol for pentagalloylglucose to above 1,700 g/mol for decagalloylglucose. This distribution, not free gallic acid content alone, governs protein-binding capacity, astringency, and aqueous hydrolysis behaviour.

Raw gallnut lots vary in gallotannin content depending on growing altitude, harvest time, and aphid population density. Manufacturer blending and normalisation are necessary to bring final API lots within specified monograph limits. Suppliers monitor gallic acid-to-tannin ratio, glucose release after hydrolysis, and polyphenolic molecular weight distribution. The extraction process usually uses hot water or aqueous alcohol followed by filtration, decolourisation, concentration, and spray-drying or vacuum-drying. Spray-dried powder tends to have a bulk density of 0.35–0.50 g/mL, lower dusting, and faster aqueous dispersion; vacuum-dried material is denser and less hygroscopic but may require additional milling. Batch-to-batch variability in residual glucose and galloylation degree is controlled by normalisation and not by terminal blending alone.

Release Limits and Chromatographic Identity for the Hydrolysable Tannin Fraction

The release profile is controlled by orthogonal methods because the hide-powder titration captures total gallotannins but does not resolve the galloylation degree. A representative specification is provided for development use; exact limits are defined by the purchaser–supplier quality agreement and the applicable pharmacopoeial monograph. For oral and injectable development, the following tests are applied.

Free gallic acid is the critical purity marker because it indicates premature hydrolysis during extraction, storage, or drying. HPLC is performed on an octadecylsilyl column with a water–acetonitrile mobile phase containing 0.1% trifluoroacetic acid and ultraviolet detection at 270 nm. The free gallic acid limit prevents lot-to-lot variation in aqueous solubility, colour, and protein binding from reaching the finished dosage form. For injectable development, the endotoxin specification replaces the non-sterile oral limit, and particulate matter is assessed on the finished injection rather than on the API.

Oral dosage forms of Galla chinensis-derived extract are used in astringent, antidiarrheal, and antimicrobial preparations; the Chinese Pharmacopoeia 2020 edition lists Galla chinensis as a traditional medicine input. The API is incorporated into tablets by wet granulation, into capsules by filling milled granules, and into granules for oral suspension by fluid-bed spraying onto sucrose or mannitol carriers. Each route requires a different particle-size and moisture specification: oral granules may permit a wider particle-size band, whereas injectable grade is lyophilised and must be free of visible foreign matter.

What Limits Aqueous Stability in Injectable Formulations?

Hydrolysable tannins undergo pH-dependent ester hydrolysis. At pH above 6.0 and at autoclave temperatures above 121 °C, polygalloylglucose esters degalloylate to free gallic acid and lower-molecular-weight oligomers. Parenteral processing therefore avoids terminal steam sterilisation of aqueous solutions when the molecular-weight distribution is critical. A lyophilised powder is prepared by dissolution in Water for Injection at pH 4.0–5.0, sterile filtration through a low-protein-binding membrane, filling, and freeze-drying. The solution is nitrogen-blanketed because dissolved oxygen accelerates oxidative darkening and free-radical-mediated degradation.

Sterile filtration must be qualified for adsorptive losses. Nylon and certain polyvinylidene fluoride membranes can remove polyphenolic fractions; polyethersulfone or polytetrafluoroethylene filters are evaluated according to PDA Technical Report 26. Injectable-grade material such as CGT-98-I is controlled for total aerobic microbial count below 100 CFU/g, bacterial endotoxin below 0.25 EU/mg, and subvisible particulate matter compatibility per USP <788>. The API is not autoclaved; depyrogenation is applied to containers and components. In formulation, avoid combination with ferric iron, alkaloid drugs, and protein-based excipients unless compatibility studies are performed because gallotannins form flocculent precipitates or blue-black ferric complexes. Once reconstituted, the aqueous solution should be used within 8 h and stored below 25 °C to limit gallic acid formation.

When High-Shear Wet Granulation Reaches the Overwetting Threshold

Wet granulation is used to improve tablet content uniformity, but the process window narrows because gallotannin fractions bind water rapidly. In a 25 L high-shear granulator with impeller speed of 200–300 rpm and chopper speed of 1,500 rpm, water addition beyond approximately 8–10% w/w of dry granulate can produce an overwetted mass that sticks to the bowl wall and yields non-uniform granule growth. Typical practice is to use a binder solution of 3–5% povidone or hydroxypropyl methylcellulose and to add the binder over 2–3 min under impeller load monitoring. The wet mass is dried at 45–50 °C in a fluid-bed dryer to a final loss on drying below 3.0%. Drying above 60 °C is avoided because thermal degalloylation can raise free gallic acid and darken the granulate. Milled granules are blended with 0.5–1.0% magnesium stearate and 0.5–1.5% colloidal silicon dioxide before compression.

For capsule filling, granules are filled into hydroxypropyl methylcellulose shells rather than high-moisture gelatin shells when storage humidity exceeds 60% RH; gallotannins can cross-link gelatin under accelerated conditions and delay dissolution. Dissolution of finished tablets should be evaluated per USP <711> using apparatus II at 50 rpm in 0.1 N hydrochloric acid or water, but the method must be product-specific. Hot-melt extrusion above 100 °C is generally avoided because the gallotannin ester bonds are thermally labile; published data for hot-melt extrusion of Chinese gallnut API is limited, and preformulation stability data are required before selecting a lipid carrier or solid dispersion platform.

Comparing Chinese Gallnut API With Turkish Gallnut and Synthetic Gallic Acid

Chinese gallnut API differs from Turkish gallnut extract and synthetic gallic acid in compositional profile and processing risk. Turkish gallnut extract contains a higher ellagitannin fraction; acid hydrolysis releases ellagic acid, which is poorly soluble and can precipitate in aqueous formulations. Synthetic gallic acid is a single molecular entity that does not reproduce the multi-site protein binding of polygalloylglucose esters.

These compositional differences are relevant in manufacturing when a formulation requires high gallotannin content without the solubility risk of ellagic acid. For injectable applications, the CGT-98-I grade should be stored below 25 °C, protected from light, and used within 8 h after reconstitution; oral granules should be packaged in double polyethylene-lined fiber drums with desiccant because the product darkens and clumps at relative humidity above 60%. Avoid contact with uncoated carbon steel and copper equipment, and use 316L stainless steel or fluoropolymer-lined contact surfaces during manufacturing.